About Bristol-Myers Squibb (NYSE:BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for the treatment of anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a strategic development and commercialization collaboration agreement with Nektar Therapeutics. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio17.15
Forward P/E Ratio16.03
Sales & Book Value
Annual Sales$20.78 billion
Price / Sales4.06
Cash Flow$3.4661 per share
Price / Cash14.89
Book Value$7.24 per share
Price / Book7.13
EPS (Most Recent Fiscal Year)$3.01
Net Income$1.01 billion
Return on Equity35.43%
Return on Assets14.85%
Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions
What is Bristol-Myers Squibb's stock symbol?
Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."
How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?
Bristol-Myers Squibb announced a quarterly dividend on Thursday, March 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share on Tuesday, May 1st. This represents a $1.60 annualized dividend and a yield of 3.10%. The ex-dividend date of this dividend is Thursday, April 5th. View Bristol-Myers Squibb's Dividend History.
How were Bristol-Myers Squibb's earnings last quarter?
Bristol-Myers Squibb (NYSE:BMY) posted its quarterly earnings results on Monday, February, 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. The biopharmaceutical company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm's quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business earned $0.63 EPS. View Bristol-Myers Squibb's Earnings History.
When is Bristol-Myers Squibb's next earnings date?
What guidance has Bristol-Myers Squibb issued on next quarter's earnings?
Bristol-Myers Squibb updated its FY18 earnings guidance on Monday, February, 5th. The company provided earnings per share (EPS) guidance of $3.15-3.30 for the period, compared to the Thomson Reuters consensus estimate of $3.23.
What price target have analysts set for BMY?
20 equities research analysts have issued 12 month price objectives for Bristol-Myers Squibb's shares. Their predictions range from $47.00 to $78.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $64.5269 in the next year. View Analyst Ratings for Bristol-Myers Squibb.
What are Wall Street analysts saying about Bristol-Myers Squibb stock?
Here are some recent quotes from research analysts about Bristol-Myers Squibb stock:
- 1. According to Zacks Investment Research, "Bristol-Myers’ blockbuster drug Opdivo is facing competitive challenges in the United States. With the FDA approving Merck’s Keytruda, for the first-line treatment of metastatic non-squamous NSCLC, the competition will stiffen up. Pricing concerns, stiff competition in the HCV and immuno-oncology space are expected to remain a significant overhang on the company’s shares. Yervoy’s sales are expected to be under pressure due to adoption of Opdivo in adjuvant melanoma. Gross margin is also expected to be under pressure due to product mix and declines in virology business. Shares of the company have underperformed the industry in the last three months. Estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (1/29/2018)
- 2. Robert W. Baird analysts commented, "The broader opportunity for 2125, theoretically, is it could be used in many different tumor types and many different cancer indications." (4/25/2017)
Who are some of Bristol-Myers Squibb's key competitors?
Some companies that are related to Bristol-Myers Squibb include Merck & Co. (MRK), AbbVie (ABBV), Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY) and Shiseido (SSDOY).
Who are Bristol-Myers Squibb's key executives?
Bristol-Myers Squibb's management team includes the folowing people:
- Dr. Giovanni Caforio, Chairman & CEO (Age 53)
- Mr. Charles A. Bancroft, CFO & Exec. VP of Global Bus. Operations (Age 58)
- Dr. Thomas J. Lynch Jr., Exec. VP of R&D and Chief Scientific Officer (Age 57)
- Ms. Sandra Leung, Exec. VP & Gen. Counsel (Age 57)
- Mr. Murdo Gordon, Exec. VP & Chief Commercial Officer (Age 51)
Has Bristol-Myers Squibb been receiving favorable news coverage?
Media headlines about BMY stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bristol-Myers Squibb earned a news sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Bristol-Myers Squibb?
Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bristol-Myers Squibb's stock price today?
One share of BMY stock can currently be purchased for approximately $51.61.
How big of a company is Bristol-Myers Squibb?
Bristol-Myers Squibb has a market capitalization of $85.51 billion and generates $20.78 billion in revenue each year. The biopharmaceutical company earns $1.01 billion in net income (profit) each year or $3.01 on an earnings per share basis. Bristol-Myers Squibb employs 23,700 workers across the globe.
How can I contact Bristol-Myers Squibb?
Bristol-Myers Squibb's mailing address is 345 PARK AVE, NEW YORK NY, 10154. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]
MarketBeat Community Rating for Bristol-Myers Squibb (BMY)MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
Bristol-Myers Squibb (NYSE:BMY) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Bristol-Myers Squibb in the last 12 months. Their average twelve-month price target is $64.5269, suggesting that the stock has a possible upside of 25.03%. The high price target for BMY is $78.00 and the low price target for BMY is $47.00. There are currently 1 sell rating, 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Hold."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Buy||Hold|
|Consensus Rating Score: ||2.40||2.42||2.50||2.44|
|Ratings Breakdown: ||1 Sell Rating(s)|
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$64.5269||$67.1333||$65.2308||$63.50|
|Price Target Upside: ||25.03% upside||1.61% upside||4.50% upside||1.06% downside|
Bristol-Myers Squibb (NYSE:BMY) Consensus Price Target History
Bristol-Myers Squibb (NYSE:BMY) Analyst Ratings History
(Data available from 4/19/2016 forward)
Bristol-Myers Squibb (NYSE:BMY) Dividend Information
Bristol-Myers Squibb pays an annual dividend of $1.60 per share, with a dividend yield of 3.10%. BMY's next quarterly dividend payment will be made on Tuesday, May 1. The company has grown its dividend for the last 8 consecutive years and is increasing its dividend by an average of 2.70% each year. Bristol-Myers Squibb pays out 53.16% of its earnings out as a dividend.
|Dividend Growth:||2.70% (3 Year Average)|
|Payout Ratio:||53.16% (Trailing 12 Months of Earnings) |
49.69% (Based on This Year's Estimates)
41.99% (Based on Next Year's Estimates)
|Track Record:||8 Years of Consecutive Dividend Growth|
Bristol-Myers Squibb (NYSE:BMY) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Bristol-Myers Squibb (NYSE BMY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 71.51%
Bristol-Myers Squibb (NYSE BMY) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/15/2017||Theodore R Samuels II||Director||Buy||4,000||$62.30||$249,200.00||22,000|| |
|12/12/2017||Thomas J Jr. Lynch||EVP||Sell||5,300||$63.24||$335,172.00||9,251|| |
|12/4/2017||Sandra Leung||EVP||Sell||156,582||$63.37||$9,922,601.34||584,373|| |
|9/6/2017||Joseph C Caldarella||SVP||Sell||9,340||$60.00||$560,400.00||46,297|| |
|8/2/2017||Theodore R Samuels II||Director||Buy||6,000||$55.94||$335,640.00||18,000|| |
|4/7/2017||Lamberto Andreotti||Director||Sell||34,000||$53.26||$1,810,840.00||952,571|| |
|3/28/2017||Lamberto Andreotti||Director||Sell||34,000||$56.17||$1,909,780.00||986,112|| |
|3/27/2017||Lamberto Andreotti||Director||Sell||17,000||$56.14||$954,380.00||986,112|| |
|3/17/2017||Louis S Schmukler||Insider||Sell||5,000||$56.49||$282,450.00||21,483|| |
|3/15/2017||Joseph C Caldarella||SVP||Sell||8,096||$57.29||$463,819.84||55,637|| |
|3/6/2017||Sandra Leung||EVP||Sell||92,405||$57.02||$5,268,933.10||488,063|| |
|2/27/2017||Theodore R Samuels II||Director||Buy||12,000||$56.77||$681,240.00||12,000|| |
|9/8/2016||Lamberto Andreotti||Director||Sell||21,600||$56.87||$1,228,392.00||334,499|| |
|8/25/2016||Lamberto Andreotti||Director||Sell||23,200||$59.17||$1,372,744.00||364,999|| |
|7/8/2016||Lamberto Andreotti||Director||Sell||23,200||$74.45||$1,727,240.00||380,099|| |
|6/28/2016||Lamberto Andreotti||Director||Sell||23,200||$72.14||$1,673,648.00||403,094|| |
|6/14/2016||John E Elicker||SVP||Sell||11,820||$72.69||$859,195.80||55,011|| |
|5/20/2016||Charles A Bancroft||CFO||Sell||30,201||$70.79||$2,137,928.79||184,694|| |
|5/16/2016||Joseph C Caldarella||SVP||Sell||3,519||$72.47||$255,021.93||55,238|| |
|5/6/2016||Sandra Leung||EVP||Sell||72,544||$70.39||$5,106,372.16||444,507|| |
|5/5/2016||Lamberto Andreotti||Director||Sell||23,200||$70.54||$1,636,528.00||425,194|| |
|5/3/2016||Giovanni Caforio||CEO||Sell||34,594||$71.31||$2,466,898.14||132,263|| |
|5/2/2016||Autenried Paul Von||SVP||Sell||37,258||$71.93||$2,679,967.94||128,463|| |
|5/2/2016||Lamberto Andreotti||Director||Sell||234,720||$71.88||$16,871,673.60||536,794|| |
|5/2/2016||Louis S Schmukler||Insider||Sell||22,218||$71.95||$1,598,585.10||21,971|| |
|4/5/2016||Lamberto Andreotti||Director||Sell||23,200||$65.90||$1,528,880.00||453,094|| |
|4/4/2016||Lamberto Andreotti||Director||Sell||11,600||$65.79||$763,164.00||453,094|| |
|3/9/2016||Lamberto Andreotti||Director||Sell||23,200||$65.71||$1,524,472.00||381,254|| |
|3/8/2016||Lewis B Campbell||Director||Sell||2,500||$66.00||$165,000.00||2,500|| |
|3/4/2016||Joseph C Caldarella||SVP||Sell||12,962||$64.64||$837,863.68||46,322|| |
|2/17/2016||Giovanni Caforio||CEO||Sell||12,040||$63.58||$765,503.20||76,738|| |
|2/17/2016||Sandra Leung||EVP||Sell||10,152||$63.57||$645,362.64||309,547|| |
|2/12/2016||Lamberto Andreotti||Director||Sell||23,200||$59.61||$1,382,952.00||392,854|| |
|1/5/2016||Lamberto Andreotti||Director||Sell||23,200||$67.56||$1,567,392.00||310,424|| |
|1/4/2016||Lamberto Andreotti||Director||Sell||11,600||$66.93||$776,388.00||310,424|| |
|12/15/2015||Lamberto Andreotti||Director||Sell||23,200||$69.03||$1,601,496.00||332,852|| |
|11/20/2015||Lamberto Andreotti||Director||Sell||23,200||$67.39||$1,563,448.00||456,052|| |
|10/6/2015||Lamberto Andreotti||Director||Sell||23,200||$60.86||$1,411,952.00||524,252|| |
|9/3/2015||Lamberto Andreotti||Director||Sell||23,200||$59.40||$1,378,080.00||546,874|| |
|6/4/2015||Joseph C Caldarella||SVP||Sell||16,972||$65.71||$1,115,230.12|| |
|3/16/2015||Francis M Cuss||EVP||Sell||114,666||$67.81||$7,775,501.46|| |
|3/16/2015||Louis S Schmukler||Insider||Sell||12,000||$66.96||$803,520.00|| |
|2/17/2015||Sandra Leung||General Counsel||Sell||11,746||$60.39||$709,340.94|| |
|2/12/2015||Samuel J Moed||SVP||Sell||3,880||$59.26||$229,928.80|| |
|2/6/2015||Samuel J Moed||SVP||Sell||21,478||$60.15||$1,291,901.70|| |
|1/29/2015||Lamberto Andreotti||CEO||Sell||90,246||$61.14||$5,517,640.44|| |
|1/29/2015||Lewis B Campbell||Director||Sell||2,500||$60.89||$152,225.00|| |
|1/29/2015||Louis S Schmukler||Insider||Sell||5,250||$60.73||$318,832.50|| |
|12/5/2014||Lamberto Andreotti||CEO||Sell||75,000||$60.31||$4,523,250.00|| |
|10/24/2014||Lamberto Andreotti||CEO||Sell||50,000||$53.00||$2,650,000.00|| |
|10/6/2014||Lamberto Andreotti||CEO||Sell||50,000||$50.99||$2,549,500.00|| |
|9/16/2014||Francis M Cuss||EVP||Sell||63,667||$50.77||$3,232,373.59|| |
|9/15/2014||Giovanni Caforio||COO||Sell||26,691||$49.87||$1,331,080.17|| |
|9/10/2014||Joseph C Caldarella||SVP||Sell||7,415||$51.03||$378,387.45|| |
|9/8/2014||Lamberto Andreotti||CEO||Sell||50,000||$51.05||$2,552,500.00|| |
|8/19/2014||Autenried Paul Von||SVP||Sell||20,000||$49.89||$997,800.00|| |
|7/29/2014||Charles A Bancroft||CFO||Sell||67,621||$51.06||$3,452,728.26|| |
|7/28/2014||Samuel J Moed||SVP||Sell||25,752||$49.32||$1,270,088.64|| |
|3/13/2014||Joseph Caldarella||SVP||Sell||9,137||$55.20||$504,362.40||68,965|| |
|3/10/2014||Lamberto Andreotti||CEO||Sell||100,000||$55.52||$5,552,000.00||630,783|| |
|3/10/2014||Louis Schmukler||Insider||Sell||8,799||$55.81||$491,072.19||8,861|| |
|3/5/2014||James Cornelius||Director||Sell||100,000||$55.82||$5,582,000.00||273,393|| |
|2/28/2014||Louis Schmukler||Insider||Sell||6,088||$54.49||$331,735.12||14,696|| |
|2/24/2014||Giovanni Caforio||EVP||Sell||41,563||$54.44||$2,262,689.72||49,753|| |
|2/19/2014||John Elicker||SVP||Sell||9,534||$54.22||$516,933.48||32,740|| |
|2/18/2014||Francis Cuss||EVP||Sell||29,800||$54.61||$1,627,378.00||207,237|| |
|2/14/2014||Charles Bancroft||CFO||Sell||52,963||$54.35||$2,878,539.05||77,303|| |
|2/14/2014||Sandra Leung||General Counsel||Sell||10,490||$54.28||$569,397.20||195,855|| |
|2/11/2014||Lamberto Andreotti||CEO||Sell||86,075||$52.66||$4,532,709.50||500,487|| |
|2/6/2014||Joseph Caldarella||SVP||Sell||35,471||$48.90||$1,734,531.90||59,355|| |
|2/5/2014||Lewis Campbell||Director||Sell||2,500||$48.28||$120,700.00|| |
|2/4/2014||James Cornelius||Director||Sell||100,000||$48.90||$4,890,000.00||373,393|| |
|7/29/2013||James M Cornelius||Director||Sell||5,000||$43.81||$219,050.00|| |
|6/10/2013||Autenried Paul Von||SVP||Sell||25,000||$47.24||$1,181,000.00|| |
|6/6/2013||Joseph C Caldarella||SVP||Sell||26,275||$46.53||$1,222,575.75|| |
|6/5/2013||John E Elicker||SVP||Sell||25,997||$46.33||$1,204,441.01|| |
|6/4/2013||Lamberto Andreotti||CEO||Sell||100,000||$47.74||$4,774,000.00|| |
|6/4/2013||Samuel J Moed||SVP||Sell||58,898||$47.38||$2,790,587.24|| |
|6/3/2013||Elliot Sigal||EVP||Sell||83,647||$48.18||$4,030,112.46|| |
|5/31/2013||Beatrice J Cazala||EVP||Sell||91,282||$47.00||$4,290,254.00|| |
|5/31/2013||Giovanni Caforio||Insider||Sell||10,538||$47.06||$495,918.28|| |
|5/30/2013||Beatrice J Cazala||EVP||Sell||22,000||$47.00||$1,034,000.00|| |
|5/28/2013||Charles A Bancroft||CFO||Sell||25,000||$48.68||$1,217,000.00|| |
|5/28/2013||James M Cornelius||Director||Sell||100,000||$47.61||$4,761,000.00|| |
|5/23/2013||Beatrice J Cazala||EVP||Sell||96,000||$46.99||$4,511,040.00|| |
|5/23/2013||Giovanni Caforio||Insider||Sell||26,647||$46.29||$1,233,489.63|| |
|5/17/2013||James M Cornelius||Director||Sell||225,996||$42.99||$9,715,568.04|| |
|5/8/2013||James M Cornelius||Director||Sell||20,000||$39.85||$797,000.00|| |
|5/2/2013||James M Cornelius||Director||Sell||20,000||$39.76||$795,200.00|| |
|4/11/2013||James M Cornelius||Director||Sell||20,000||$41.15||$823,000.00|| |
|3/13/2013||James M Cornelius||Director||Sell||20,000||$38.18||$763,600.00|| |
|3/13/2013||John E Elicker||SVP||Sell||3,409||$38.51||$131,280.59|| |
|2/27/2013||Giovanni Caforio||Insider||Sell||12,150||$37.08||$450,522.00|| |
|2/26/2013||James M Cornelius||Director||Sell||20,000||$36.58||$731,600.00|| |
|1/17/2013||James M Cornelius||Director||Sell||20,000||$34.33||$686,600.00|| |
|12/28/2012||James M Cornelius||Director||Sell||20,000||$32.06||$641,200.00|| |
|10/3/2012||James M Cornelius||Director||Sell||20,000||$33.71||$674,200.00|| |
|8/10/2012||James M Cornelius||Director||Sell||10,000||$31.81||$318,100.00|| |
Bristol-Myers Squibb (NYSE BMY) News Headlines
Bristol-Myers Squibb (NYSE:BMY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Bristol-Myers Squibb (NYSE:BMY) Income Statement, Balance Sheet and Cash Flow Statement
Bristol-Myers Squibb (NYSE BMY) Stock Chart for Thursday, April, 19, 2018